Updated Equifax executives sold stock after data breach, before informing public 9:05 P.M. ET SpaceX blasts top-secret X-37B ‘space plane’ into orbit 9:01 P.M. ET Trump’s debt deal with Democrats is anything but normal ...
Following the news, La Jolla Pharmaceutical's stock price spiked 81%, trading at $36.15 per share, up $16.28, on Monday afternoon. (See also, Boston Scientific Recalls Lotus Heart Devices.) In the placebo-compared Phase 3 study of LJPC
Ultimately, LJPC-501 posted a statistically significant response to the trial that met the primary endpoint. Excluding Monday’s move, the stock was up 13% year to date. Over the past 52 weeks, it is actually up 29%. The stock hit a …
Today, our research desk covers a blog story on LJPC. Go directly to your stock of interest and access today's free …
The stock price is soaring for local drugmaker La Jolla Pharmaceutical Co. following promising clinical trial data on its experimental blood pressure drug. The local company is studying the drug, called LJPC-501, in patients who have …
After announcing that its phase 3 ATHOS-3 study would be published in a prestigious medical journal, clinical-stage biotech La Jolla Pharmaceutical (NASDAQ: LJPC) saw its shares ... David and Tom Gardner have a stock tip, it can …
ETRM closed Monday's trading at $1.94, up 1.57%. In after-hours, the stock gained another 7.73% to $2.09. La Jolla Pharmaceutical Co.'s (LJPC) New Drug Application for LJPC-501 for the treatment of hypotension in adults with …
La Jolla Pharmaceutical Company (NASDAQ: LJPC) announced that it has called a ... available for distribution to holders of the approximately 66M shares of common stock issued and outstanding.